These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37800793)

  • 21. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Al-Samkari H; Kolb-Sielecki J; Safina SZ; Xue X; Jamieson BD
    Lancet Haematol; 2022 Mar; 9(3):e179-e189. PubMed ID: 35240074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of avatrombopag for the treatment of thrombocytopenia.
    Virk ZM; Kuter DJ; Al-Samkari H
    Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
    [No Abstract]   [Full Text] [Related]  

  • 24. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
    Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
    J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
    Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
    Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
    Abdela J
    Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic platelet transfusions prior to surgery for people with a low platelet count.
    Estcourt LJ; Malouf R; Doree C; Trivella M; Hopewell S; Birchall J
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012779. PubMed ID: 30221749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease.
    Mladsi D; Barnett C; Aggarwal K; Vredenburg M; Dieterich D; Kim R
    Clinicoecon Outcomes Res; 2020; 12():515-526. PubMed ID: 32982341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avatrombopag for the salvage treatment of platelet transfusion refractoriness.
    Qin Y; Wang Y; Zhang Y; Jiao Y; Ye J
    Ther Adv Hematol; 2024; 15():20406207241237606. PubMed ID: 38481948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
    Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
    BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Romiplostim for the management of perioperative thrombocytopenia.
    Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
    Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease.
    Lozano ML
    Rev Esp Enferm Dig; 2021 Feb; 113(2):136-140. PubMed ID: 33233913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
    Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis.
    Lu J; Jamieson BD; Hui AM
    Therap Adv Gastroenterol; 2022; 15():17562848221105976. PubMed ID: 35795378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
    Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U
    World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
    Nomoto M; Ferry J; Hussein Z
    J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.
    Nomoto M; Pastino G; Rege B; Aluri J; Ferry J; Han D
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):188-195. PubMed ID: 28339166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avatrombopag: First Global Approval.
    Shirley M
    Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.